A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT02665234 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG: 1% Tavilermide Ophthalmic Solution
DRUG: Placebo Ophthalmic Solution

Sponsor

Mimetogen Pharmaceuticals USA, Inc.